ASeq Newsletter

ASeq Newsletter

Nautilus Makes Me Sad

Jul 29, 2026
∙ Paid

The company recently announced Q2 results, with essentially no revenue1. And GenomeWeb is reporting that their “broadscale” platform is delayed. I’ve not been keeping track of deadlines on this as my assumption has been that this will come in “this distant future” and I don’t believe we’ve seen any data from this yet…

Anyway… let’s discuss why Nautilus makes me sad.

All Biotechs Are Beautiful

Part of me is sympathetic to any and all Biotech companies. Because Biotech gets such a small slice of the overall funding pie. If we look at all Biotech exits, my estimates suggest we are somewhere in the $300B/yr range:

This post is for paid subscribers

Already a paid subscriber? Sign in
© 2026 Nava Whiteford · Privacy ∙ Terms ∙ Collection notice
Start your SubstackGet the app
Substack is the home for great culture